Rare Mutations and Fusions Patient Gateway
About rare mutations and fusions in lung cancer
Currently, there are nine DNA-based alterations, or biomarkers, for which we have targeted therapies in NSCLC. Rare mutations and fusions include BRAF V600E, MET, NTRK, RET and ROS1.
LATEST UPDATES
-
Researcher Goes Against the Grain: Brings New Hope for Patients with BRAF Fusions
Read time: 4 minutes. BRAF is an important signaling protein that regulates how normal cells grow and multiply through the MAPK (mitogen activated protein kinase) signaling pathway... -
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
Read time: 3 minutes. For people with advanced or metastatic non-small cell lung cancer (NSCLC), the treatment landscape has changed dramatically in recent years. Researchers are... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community...
Sponsors
